Doubling Down on Mutant RAS Can MEK or Break Leukemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28235190.
- Also identified by DOI 10.1016/j.cell.2017.02.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of Kras<sup>G12D</sup> mutant acute myeloid leukemia and propose its use as a predictive biomarker.
Medical subject headings
- Mutation
- Protein Kinase Inhibitors